Introducing HPV Vaccine in Developing Countries — Key Challenges and Issues

Também do New England Journal of Medicine ressalvo parte do Editorial

The factors with the greatest influence on the cost-effectiveness of vaccination will be the price of the vaccine and the costs of a program to reach adolescents. An analysis of options for cervical-cancer control in Brazil found that at a cost of $5 per dose (excluding wastage, administration, and costs of programs), the cost-effectiveness ratio associated with adolescent vaccination would be less than $150 per year of life saved, and vaccination combined with screening women three times during their lifetime would meet the criteria for a very cost-effective intervention.³ At a price of $100 per dose, vaccination would not be cost-effective, as compared with screening three times per lifetime. For countries with a gross domestic product of less than $1,000 per capita, the per-dose cost may need to be as low as $1 to $2 to make vaccination both cost-effective and affordable.